Literature DB >> 22038876

Adjunct therapeutic plasma exchange for anti-N-methyl-D-aspartate receptor antibody encephalitis: a case report and review of literature.

M Kamran Mirza1, Jennifer Pogoriler, Kristen Paral, Vijayalakshmi Ananthanarayanan, Saptarshi Mandal, Abdul Mazin, Beverly Baron, Elie Richa.   

Abstract

Encephalitis associated with autoantibodies directed against the N-methyl-D-aspartate receptor (NMDAR) is usually a paraneoplastic syndrome that presents in young females with ovarian teratomas. We report a case of a previously healthy 14-year-old girl with sudden-onset paranoia, hallucinations, hyperactivity, increased speech, decreased sleep, seizures, and violent behavior deteriorating to catatonia. Her cerebrospinal fluid tested positive for anti-NMDAR antibodies. She was treated with five sessions of therapeutic plasma exchange (TPE) after having failed therapy with antibiotics, intravenous steroids, intravenous immunoglobulin (IVIG), one dose of rituximab, and seven sessions of electroconvulsive therapy (ECT). The American Society for Apheresis assigns a Category III (Grade 2C) recommendation for TPE in paraneoplastic neurologic syndromes; however, apheresis specifically for anti-NMDAR encephalitis has not been well studied. Literature review revealed two case reports describing outstanding improvement in patients with anti-NMDAR encephalitis following TPE. We report no improvement in our patient's symptoms after plasma exchange and discuss possible reasons for why it failed along with review of the literature.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22038876     DOI: 10.1002/jca.20312

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  7 in total

1.  Successful treatment of anti-NMDA receptor encephalitis with a prompt ovarian tumour removal and prolonged course of plasmapheresis: A case report.

Authors:  Elzbieta Rypulak; Michal Borys; Pawel Piwowarczyk; Magdalena Fijalkowska; Beata Potrec; Justyna Sysiak; Janusz Spustek; Alicja Bartkowska-Sniatkowska; Jan Kotarski; Waldemar A Turski; Konrad Rejdak; Miroslaw Czuczwar
Journal:  Mol Clin Oncol       Date:  2016-10-19

2.  Anti-N-methyl-D-aspartate receptor encephalitis in a pre-teenage girl: a case report.

Authors:  Stephanie Nijmeijer; Sander Bontemps; Leonie Naeije; Jonathan Coutinho
Journal:  Eur J Pediatr       Date:  2013-05-24       Impact factor: 3.183

3.  Anti-N-methyl-d-aspartate receptor encephalitis in a patient with a 7-year history of being diagnosed as schizophrenia: complexities in diagnosis and treatment.

Authors:  Chaohua Huang; Yukun Kang; Bo Zhang; Bin Li; Changjian Qiu; Shanming Liu; Hongyan Ren; Yanchun Yang; Xiehe Liu; Tao Li; Wanjun Guo
Journal:  Neuropsychiatr Dis Treat       Date:  2015-06-11       Impact factor: 2.570

Review 4.  Utility of Plasmapheresis in Autoimmune-Mediated Encephalopathy in Children: Potentials and Challenges.

Authors:  Abdulhafeez M Khair
Journal:  Neurol Res Int       Date:  2016-04-28

Review 5.  Pediatric Anti-N-Methyl-d-Aspartate Receptor Encephalitis: A Review with Pooled Analysis and Critical Care Emphasis.

Authors:  Kenneth E Remy; Jason W Custer; Joshua Cappell; Cortney B Foster; Nan A Garber; L Kyle Walker; Liliana Simon; Dayanand Bagdure
Journal:  Front Pediatr       Date:  2017-11-24       Impact factor: 3.418

6.  A successful case of anti-NMDAR encephalitis without tumor treated with a prolonged regimen of plasmapheresis.

Authors:  Mateus Mistieri Simabukuro; Rafael Gustavo Sato Watanabe; Lécio Figueira Pinto; Carla Guariglia; Daniella Costa de Menezes E Gonçalves; Renato Anghinah
Journal:  Dement Neuropsychol       Date:  2014 Jan-Mar

7.  Successful treatment of anti-NMDA receptor encephalitis with early teratoma removal and plasmapheresis: A case report.

Authors:  Monica Gomes Ferreira; Victoria Lapresa Alcalde; María Helena García Sánchez; Lourdes Hernández Hernández; María José Doyague Sánchez
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.